SERPINB4 (Serpin Family B Member 4)

However, larger-scale studies will still be needed in the future to guide clinical decisions because of the limited sample size.

A panel comprising seven key IPF genes was identified, which may have diagnostic and prognostic value for IPF. A comprehensive analysis of the Dgidb database revealed potential drugs that may be antitumor agents against IPF, such as Lygodii Spora, Smilacis Glabrae Rhizoma, and Aloe.

SCCA2 reflects patient-experienced symptom burden more closely than physician-assessed severity in mild AD. Its short-term, time-dependent association with POEM suggests potential utility for identifying early or imminent symptom burden.

Clinically, SERPINB3 is highly expressed in human LUAD specimens and co-localizes with SENP3 and NPM1. Our work establishes SENP3 as a bona fide endogenous substrate of SERPINB3 and delineates a novel sumoylation-dependent oncogenic axis in LUAD, offering potential therapeutic targets for this malignancy.

Furthermore, drug sensitivity analysis indicated that the high-risk group exhibited increased sensitivity to Axitinib, while the low-risk group showed higher responsiveness to drugs such as cisplatin. It not only serves as a predictor of patient survival but also provides a theoretical foundation for personalized immunotherapy and drug selection. Future research should focus on further validating the clinical applicability of this model and exploring its potential in the context of immunotherapy and targeted therapies.

METTL3 promotes PVT1 stability through m6A deposition and upregulates its expression in OSCC, which could upregulate SERPINB4 by sponging miR-185-5p, and ultimately promoting OSCC growth and metastasis. These findings suggest that PVT1 could serve as a potential biomarker and therapeutic target for OSCC.

Indeed, higher expression of TRIM29, S100P and β-catenin associates with reduced recurrence free survival. This work proposes TRIM29 as an important node that modulates a unique gene network in chemoresistant TNBC and whose biological impact is mediated by modulation of S100P and β-catenin.

The findings suggest that non-invasive measurements of corneal SCCA1 at 2 months of age is useful for predicting atopic dermatitis and food allergy in infants at risk for atopic dermatitis and subsequent food allergy.

Moreover, although several biomarkers showed good ability to monitor the efficacy of molecularly targeted drugs against AD. More studies for discovery and development of biomarkers of AD are awaited to refine treatments for AD patients.

We recommend a cutoff value of 1.8 ng/mL for SCCA-1 in IP diagnosis. SCCA-1 and SCCA-2 when combined with imaging and pathology hold promise for enhancing the preoperative detection of IP, which would be a valuable contribution to clinical practice.

This study is the first to correlate serum SCCA level with proSPI-s. Moreover, SCCA was measured using a widely available kit. SCCA may be used to assess the severity of psoriasis.

We further revealed that SERPINB3 promoted STAT-dependent expression of chemokines, whereby inhibition of STAT activation by ruxolitinib or siRNA abrogated CXCL1/8 and S100A8/ A9 expression in SERPINB3 cells. Patients with elevated pre-treatment SCCA and high pSTAT3 had increased intratumoral CD11b+ myeloid cell compared to patients with low SCCA and pSTAT3 cohort that had overall improved survival after radiotherapy. These findings provide a preclinical rationale for targeting SERPINB3 in tumors to counteract the immunosuppression and improve response to radiation.